公开(公告)号：US11629172B2

公开(公告)日：2023-04-18

申请号：US16721229

申请日：2019-12-19

Applicant: Pfizer Inc.

Inventor： Philip Ralph Dormitzer ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Seungil Han ,  Kyle Paul Heim ,  Thomas Richard Jones ,  Yuhang Liu ,  Xiayang Qiu ,  Xinzhen Yang ,  Xiaojie Yao ,  Matthew Curtis Griffor ,  Jennifer Anne Nicki

IPC: C07K14/005 ,  A61K39/00

Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

公开(公告)号：US20200247853A1

公开(公告)日：2020-08-06

申请号：US16721229

申请日：2019-12-19

Applicant: Pfizer Inc.

Inventor： Philip Ralph Dormitzer ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Seungil Han ,  Kyle Paul Heim ,  Thomas Richard Jones ,  Yuhang Liu ,  Xiayang Qiu ,  Xinzhen Yang ,  Xiaojie Yao ,  Matthew Curtis Griffor ,  Jennifer Anne Nicki

IPC: C07K14/005

Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.